期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

1型糖尿病的DiaPep277免疫治疗

Immunotherapy with DiaPep277 peptide in type 1 diabetes
原文传递
导出
摘要 1型糖尿病（T1DM）的病理基础是胰岛β细胞的自身免疫性破坏,因此阻止该免疫进程对预防或治疗T1DM尤为重要.DiaPep277是一种由24个氨基酸组成的肽段,衍生于热休克蛋白60（HSP60）的C-末端区域.研究证明,它对糖尿病动物模型的自身免疫性T细胞具有免疫调节作用.临床研究表明,DiaPep277对初发T1DM患者的胰岛β细胞有保护作用,并具有安全性. Type 1 diabetes mellitus （T1DM） is characterized by the autoimmune destruction of islet β cells.Blocking the immune process is important for prevention and treatment of T1DM.DiaPep277 is composed of 24 amino acids derived from the C-terminal region of heat shock proteins 60 （HSP60） and manufactured as a synthetic peptide.DiaPep277 has an immune modulatory effect on T cells in animal models of diabetes.The results of the clinical trials indicate that DiaPep277 is safe and can preserve β cell function in patients with newly diagnosed T1DM.
作者 李亚兰 项洁 卜瑞芳
机构地区 无锡市人民医院内分泌科
出处 《国际内分泌代谢杂志》 北大核心 2014年第3期169-171,共3页 International Journal of Endocrinology and Metabolism
基金 江苏省自然科学基金资助项目（BK2011177）
关键词 DiaPep277 免疫调节 1型糖尿病 DiaPep277 Immunomodulation Type 1 diabetes mellitus
分类号 R587.1 [医药卫生—内分泌]
  • 相关文献

参考文献17

  • 1Hawa MI, Kolb H, Schloot NC, et al.Adult-onset autoimmune diabetes in Europe is prevalent with a broad clinical phenotype: Action LADA 7[J] .Diabetes Care, 2013,36(4) : 908-913.
  • 2Sumpter KM,Adhikari S, Grishman EK, et al.Preliminary studies related to anti-interleukin-ll3 therapy in children with newly diagnosed type 1 diabetes [J].Pediatr Diabetes, 2011,12 (7) : 656-667.
  • 3Moran A, Bundy B, Becker DJ,et al.Interleukin- 1 antagonism in type 1 diabetes of recent onset :two multicentre,randomised, double:blind,placebo:controlled trials[J].Lancet,2013,381(9881): 1905-1915.
  • 4Herold KC,Gitelman SE,Willi SM,et al.Teplizumab treatment may improve C-peptide responses in participants with type I diabetes after the new-onset period: a randomised controlled trial[J].Diabetologia, 2013,56(2) : 391-400.
  • 5Lebastchi J,Deng S,Lebastchi AH,et al.Immune therapy and 13-cell death in type 1 diabetes[J].Diabetes,2013,62(5):1676- 1680.
  • 6Sherry N, Hagopian W, Ludvigsson J, et al.Teplizumab for treat- ment of type 1 diabetes (Prot6g study): 1-year results from a randomised,placebocontrolled trial[J].Lancet,2011,378 (9790) :487-497.
  • 7Zanin-Zhorov A,Tal G,Shivtiel S,et al.Heat shock protein 60 activates eytokine-associated negative regulator suppressor of cytokine signaling 3 in T cells:effects on signaling,chemotaxis, and inflammation[J].J Immunol, 2005,175 ( 1 ) : 276-285.
  • 8Quintana FJ,Cohen IR.The HSP60 immune system network[J]. Trends Immunol, 2011,32(2 ) : 89-95.
  • 9Raz I,Avron A,Tamir M,et al.Treatment of new-onset type 1 diabetes with peptide DiaPep277 is safe and associated with preserved beta-cell function : extension of a randomized, double- blind,phase Ⅱ trial [J].Diabetes Metab Res Rev,2007,23(4): 292-298.
  • 10Abulafia-Lapid R,Elias D,Raz I,et al.T cell proliferative responses of type 1 diabetes patients and healthy individuals to human hsp60 and its peptides [J].J Autoimmun, 1999,12 (2) : 121-129.
国际内分泌代谢杂志
2014年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部